128 related articles for article (PubMed ID: 36934366)
1. Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals.
Evans R; Kimura H; Nakashima M; Ishikawa T; Yukitake H; Suzuki M; Hazel J; Faessel H; Wu J; Hang Y; Alexander R; Rosen L; Hartman DS; Ratti E
J Sleep Res; 2023 Oct; 32(5):e13878. PubMed ID: 36934366
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia.
Mignot E; Bogan RK; Emsellem H; Foldvary-Schaefer N; Naylor M; Neuwirth R; Faessel H; Swick T; Olsson T
Sleep; 2023 Sep; 46(9):. PubMed ID: 36883238
[TBL] [Abstract][Full Text] [Related]
3. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
[TBL] [Abstract][Full Text] [Related]
4. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model.
Ishikawa T; Hara H; Kawano A; Kimura H
Pharmacol Biochem Behav; 2022 Oct; 220():173464. PubMed ID: 36108771
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacodynamics of a single infusion of danavorexton in adults with obstructive sleep apnea experiencing excessive daytime sleepiness despite adequate use of CPAP.
Bogan RK; Maynard JP; Neuwirth R; Faessel H; Swick T; Olsson T
Sleep Med; 2023 Jul; 107():229-235. PubMed ID: 37244138
[TBL] [Abstract][Full Text] [Related]
6. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
[TBL] [Abstract][Full Text] [Related]
7. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
Dauvilliers Y; Mignot E; Del Río Villegas R; Du Y; Hanson E; Inoue Y; Kadali H; Koundourakis E; Meyer S; Rogers R; Scammell TE; Sheikh SI; Swick T; Szakács Z; von Rosenstiel P; Wu J; Zeitz H; Murthy NV; Plazzi G; von Hehn C
N Engl J Med; 2023 Jul; 389(4):309-321. PubMed ID: 37494485
[TBL] [Abstract][Full Text] [Related]
8. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
[TBL] [Abstract][Full Text] [Related]
9. Novel biomarkers derived from the Maintenance of Wakefulness Test as predictors of sleepiness and response to treatment.
Tracey B; Culp M; Fabregas S; Mignot E; Buhl DL; Volfson D
Sleep; 2024 Jul; ():. PubMed ID: 38954525
[TBL] [Abstract][Full Text] [Related]
10. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
Black J; Houghton WC
Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
[TBL] [Abstract][Full Text] [Related]
11. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.
Lin JS; Dauvilliers Y; Arnulf I; Bastuji H; Anaclet C; Parmentier R; Kocher L; Yanagisawa M; Lehert P; Ligneau X; Perrin D; Robert P; Roux M; Lecomte JM; Schwartz JC
Neurobiol Dis; 2008 Apr; 30(1):74-83. PubMed ID: 18295497
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
Bogan RK; Feldman N; Emsellem HA; Rosenberg R; Lu Y; Bream G; Khayrallah M; Lankford DA
Sleep Med; 2015 Sep; 16(9):1102-8. PubMed ID: 26298786
[TBL] [Abstract][Full Text] [Related]
13. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
Ruoff C; Swick TJ; Doekel R; Emsellem HA; Feldman NT; Rosenberg R; Bream G; Khayrallah MA; Lu Y; Black J
Sleep; 2016 Jul; 39(7):1379-87. PubMed ID: 27166238
[TBL] [Abstract][Full Text] [Related]
14. Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial.
Philip P; Chaufton C; Taillard J; Capelli A; Coste O; Léger D; Moore N; Sagaspe P
Sleep; 2014 Mar; 37(3):483-7. PubMed ID: 24587570
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group.
Neurology; 2000 Mar; 54(5):1166-75. PubMed ID: 10720292
[TBL] [Abstract][Full Text] [Related]
16. Findings of the Maintenance of Wakefulness Test and its relationship with response to modafinil therapy for residual excessive daytime sleepiness in obstructive sleep apnea patients adequately treated with nasal continuous positive airway pressure.
Inoue Y; Miki M; Tabata T
Sleep Med; 2016; 27-28():45-48. PubMed ID: 27938918
[TBL] [Abstract][Full Text] [Related]
17. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness.
Schwartz JR; Nelson MT; Schwartz ER; Hughes RJ
Clin Neuropharmacol; 2004; 27(2):74-9. PubMed ID: 15252267
[TBL] [Abstract][Full Text] [Related]
18. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy.
Broughton RJ; Fleming JA; George CF; Hill JD; Kryger MH; Moldofsky H; Montplaisir JY; Morehouse RL; Moscovitch A; Murphy WF
Neurology; 1997 Aug; 49(2):444-51. PubMed ID: 9270575
[TBL] [Abstract][Full Text] [Related]
20. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.
Herring WJ; Liu K; Hutzelmann J; Snavely D; Snyder E; Ceesay P; Lines C; Michelson D; Roth T
Sleep Med; 2013 Oct; 14(10):955-63. PubMed ID: 23920422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
